rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

MiMedx Group, Inc

MDXG · Nasdaq

Health CareMedical DevicesNot moving yet

MDXG stood above a rising 150-day average in 5 of the last 52 weekly readings, and has been out of that trend for the last 43 weeks. It is 8.3% below that average now. Medical Devices: 29% of its 181 stocks in an uptrend (−4 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 43
Industry in uptrend
29% -4 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$433K
Officials’ trades on record
1
Institutions holding
212 (-6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 5 of 52 weeks.

22 Apr – 21 Oct
15%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1.0M$0$1.2MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

1 disclosed lines: House 1, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Tom Malinowski House: U.S. House ClerkNJ07sold$15k–$50k30 May 2019filed 9 Jul 2021

Insiders

Buy orders, 12 months0
Sale orders, 12 months1
Buyers · sellers0 · 1

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders212-6 on the quarter
New · exited40 · 47
Reported value$428.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Essex Woodlands Management, Inc.unchanged · filed 4 Aug 202628,195,249$108.6M00.0%
BlackRock, Inc.added · filed 7 Aug 202612,154,466$46.8M+243,166+2.0%
Trigran Investments, Inc.reduced · filed 12 Aug 20267,173,770$27.6M-1,3390.0%
STATE STREET CORPadded · filed 7 Aug 20265,578,920$21.5M+522,119+10.3%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20265,187,053$20.0M+21,047+0.4%
Nantahala Capital Management, LLCadded · filed 14 Aug 20264,767,552$18.4M+1,370,253+40.3%
PARADIGM CAPITAL MANAGEMENT INCadded · filed 13 Aug 20264,073,100$15.7M+662,800+19.4%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20263,143,488$12.1M+262,329+9.1%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 20262,665,562$10.3M+1,480,001+124.8%
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 20262,467,005$9.5M+1,554,277+170.3%
31 Mar 2023 – 30 Jun 2026
134175215Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Rice Doug Company insiderChief Financial Officer · last 2 Jul 20261 · 0
Kimberly Maersk-Moller Company insiderChief Commercial Officer · last 24 Jun 20260 · 4
Dorothy E. Puhy Company insiderDirector · last 10 Jun 20260 · 0
James L. Bierman Company insiderDirector · last 10 Jun 20260 · 0
Tiffany Olson Company insiderDirector · last 10 Jun 20260 · 0
Todd Newton Company insiderDirector · last 10 Jun 20260 · 0
William A. Hawkins Company insiderDirector · last 10 Jun 20260 · 0
William Frank Hulse IV Company insiderGeneral Counsel and CAO · last 13 Mar 20260 · 10
Joseph H. Capper Company insiderChief Executive Officer · last 4 Mar 20263 · 0
Ricci S. Whitlow Company insiderChief Operating Officer · last 4 Mar 20260 · 5
Cato T. Laurencin Company insiderDirector · last 18 Jun 20250 · 0
M. Kathleen Behrens Company insiderDirector · last 18 Jun 20250 · 0

Same industry

RCEL Avita MedicalLeading+127%
HTFL HeartflowLeading+59%
ATRC AtriCureLeading+51%
HAE HaemoneticsLeading+44%
BVS BioventusLeading+24%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202582.6%
Operating profit marginFY 2025 · to 31 Dec 202515.3%
Return on capital employedFY 2025 · to 31 Dec 202522.9%
Cash conversionFY 2025 · to 31 Dec 2025152%
Debt to equityFY 2025 · to 31 Dec 20250.08×
Research spendFY 2025 · to 31 Dec 20253.6%
Share count trendFY 2025 · to 19 Feb 20260.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$166.1M

Analyst forecasts

No analyst forecasts yet.